Advanced Oncotherapy (AVO) – Conversion of convertible loan notes

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company.  Further details of the conversion are set out […]

Advanced Oncotherapy (AVO) – Update on Bracknor financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has drawn down the third tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche), for proceeds of £1.235 million.  Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company.  Further details of the conversion are set […]

Advanced Oncotherapy (AVO) – Holdings in company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share […]

Advanced Oncotherapy (AVO) – Conversion of Convertible Loan Notes

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of […]

Advanced Oncotherapy (AVO) – Non-exec Professor Steve Myers buys 400,000 shares at 26p.

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers, Non-Executive Director of the Company, has purchased today a total of 400,000 ordinary shares of 25 pence in the Company at a price of 26 pence per Ordinary Share. Following this transaction, Professor Myers holds 450,569 Ordinary […]